In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 32 for your search:
Drug:  ziv-aflibercept
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6125, EudraCT : 2005-005026-31, AVE0005A /3001, NCT00327444

2.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6546, 2006-004756-20, NCT00519285

3.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10261, EudraCT 2007-000819-29, NCT00532155

4.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10262, EudraCT 2007-000820-42, NCT00561470

5.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00218, 2006-0329, P50CA083639, MDA-2006-0329, 7757, NCT00436501

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417

7.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD6123, AVE0005B/2001, NCT00284141

8.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD6122, AVE0005, NCT00327171

9.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01827, NCCTG-N0537, U10CA025224, CDR0000491314, N0537, NCT00369655

10.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00677, CDR0000495275, NABTC06-01, U01CA062399, ABTC-0601, NCT00369590

11.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00177, PHL-051, CDR0000508798, N01CM62209, N01CM62203, N01CM62201, PMH-PHL-051, 7502, NCI-7502, NCT00390234

12.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00176, PHL-050, CDR0000518293, N01CM62203, PMH-PHL-050, 7498, NCI-7498, NCT00407654

13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02840, PHII-76, 7533, N01CM62201, N01CM62209, CCC-PHII-76, NCT00407485

14.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD6772, EUDRACT: 2006-000604-16, NCT00396591

15.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00182, PHII-77, N01CM17101, CDR0000535719, CCC-PHII-77, 7522, NCT00450255

16.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00597, CDR0000540237, GOG-0229F, U10CA027469, NCT00462826

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00178, MSKCC-08066, CDR0000608163, 08-066, 7508, P30CA008748, N01CM62206, NCT00729157

18.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01182, SWOG-S0802, CDR0000632614, S0802, NCT00828139

19.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10668, EudraCT 2008-004178-41, NCT00851084

20.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 25 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: REGENERON-VGFT-ST-0103, MSKCC-01131, CDR0000069343, NCI-G02-2065, NCT00036946

21.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 25 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: REGENERON-VGF-ST-0105, MSKCC-02020, CDR0000256462, NCI-G-02-2101, NCT00045266

22.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: REGENERON-VGFT-ST-0304, MSKCC-03138, CDR0000360846, NCT00082823

23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: REGENERON-VGFT-ST-0202, MSKCC-03137, CDR0000360856, NCT00083213

24.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED10089, NCT00479076

25.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD10091, NCT00545246
1   
New Search